Plasma autoantibody biomarkers for basal like breast cancer
AssigneesArizona Board of Regents on behalf of Arizona State University, The U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsJoshua LaBaer, Jie Wang, Ji Qiu, Garrick Wallstrom, Karen Anderson, Jin Park, Jonine Figueroa
Life of this patent
Estimating the term…
Abstract
Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).
Claims5
A basal-like breast cancer diagnostic test kit, comprising a panel of at least two tumor antigens selected from the group consisting of:
- P53 (TP53), NYESO1 (CTAG1B), NY ESO2 (CTAG2), RNF216, PPHLN1, PIP4K2C, ZBTB16, TAS2R8, WBP2NL, DOK2, PSRC1, MN1, TRIM21, POU4F1, SSMEM1, LMO4, BCL2, KRT8, TSGA13, PVRL4, SNRK, DYRK3, RNF32, JUNB, KCNIP3, CCDC68, CSN3, TRAIP, and a suitable detection agent.
Dependencies are inferred from the claim text.